

## HR 1834

### Cancer Care Payment Reform Act of 2017

**Congress:** 115 (2017–2019, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Mar 30, 2017

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Apr 12, 2017)

**Official Text:** <https://www.congress.gov/bill/115th-congress/house-bill/1834>

## Sponsor

**Name:** Rep. McMorris Rodgers, Cathy [R-WA-5]

**Party:** Republican • **State:** WA • **Chamber:** House

## Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Sewell, Terri A. [D-AL-7]	D · AL		Mar 30, 2017

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 31, 2017
Ways and Means Committee	House	Referred to	Apr 12, 2017

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
115 S 463	Identical bill	Feb 28, 2017: Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S1502-1504)

## **Cancer Care Payment Reform Act of 2017**

This bill amends title XVIII (Medicare) of the Social Security Act to establish the Oncology Medical Home Demonstration Project, through which the Centers for Medicare & Medicaid Services (CMS) shall make special payments to participating oncology practices that coordinate patient care and meet other specified requirements.

During the first two years of the project, CMS shall pay a care coordination management fee to each such practice. After the third, fourth, and fifth years of the project, CMS shall pay a performance incentive payment to each participating practice that meets or exceeds performance standards developed by CMS.

CMS shall assess the performance of each participating oncology practice annually. Performance standards shall address: (1) specified measures related to patient care, resource utilization, survivorship, and end-of-life care; and (2) the patient experience of care, as reflected in surveys submitted by each practice. CMS shall also assess the extent to which a practice has used breakthrough or other best-in-class therapies.

To the extent practicable, CMS shall select practices of varying sizes and geographic areas for participation.

### **Actions Timeline**

---

- **Apr 12, 2017:** Referred to the Subcommittee on Health.
- **Mar 31, 2017:** Referred to the Subcommittee on Health.
- **Mar 30, 2017:** Introduced in House
- **Mar 30, 2017:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.